The Holistic Sanctuary Announces Exciting Plans to Expand Over Next 4 Years and Save More Lives – WFMZ Allentown

BEVERLY HILLS, Calif., Sept. 19, 2020 /PRNewswire/ -- The Holistic Sanctuary is proud to announce its exciting plans to grow the number of cutting-edge luxury centers it has over the next four years, allowing it to help even more patients in need of its pioneering treatments.

After a decade of revolutionizing the holistic health field and saving lives, The Holistic Sanctuary, which currently has a state-of-the-art facility in Baja California (Mexico), plans to open another center in Tulum, Mexico, as well as an additional three centers in several other locations around the world.

Holistic Sanctuary Tulum is well on its way to opening its doors in 2021, which will be followed by plans to open other centers in Tulum (2021), Malibu (2022), London (2023) and Dubai (2024).

The Holistic Sanctuary is a world-class holistic medical spa that uses cutting-edge technology and advanced therapies from around the world to cure, heal, and reverse illnesses and diseases that Western medical professionals have said are incurable. By using a combination of natural therapies, they help people to recover from a variety of different conditions such as depression, addiction, PTSD, stress, anxiety, and more.

Johnny Tabaie, CEO and Founder of The Holistic Sanctuary, said:"We are incredibly excited that we will soon be able to help even more patients around the world. We've taken holistic healing to a whole different level, and our intention has always been to heal patients using natural, effective, holistic and other alternative therapies that give results in real-time, without having to medicate people with addictive drugs.

"We simplytransform people's lives; we give them a fighting chance at a good quality oflife. We get people off prescribed medications, heal the underlying cause of PTSD, depression, trauma and even addiction, then send them back home healthy, thriving, happy and whole again."

More information on The Holistic Sanctuary's luxury drug rehab centers can be found at https://www.theholisticsanctuary.com/luxury-rehab-centers/

In addition to its growth plans, the organization has also announced that by the end of 2020 it will have the first AIDS and cancer research center that will strive to cure diseases like this using revolutionary stem cell technology. It will also be able to treat other autoimmune conditions such as lupus, rheumatoid arthritis, Lyme disease, neuropathy, multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).

This kind of cutting technology has been around for the last 30 years, revolutionizing how illnesses like these are treated through the discovery of isolated stem cell genes that have been proven clinically to showit has cured two patients suffering from AIDS and cancer. One has been clear for 10 years now, with the other being cured last year. This is a new, paradigm-shifting approach that is pushing western medication treatment to the side.

To learn about how stem cell technology is used by the centers, more information can be found here: https://www.theholisticsanctuary.com/stem-cell-therapy/

Learn more about The Holistic Sanctuary's Mexico stem cell center here: https://www.theholisticsanctuary.com/stem-cell-therapy/mexico/

The Holistic Sanctuary has an 80% success rate at healing patients that are either on medications, alcohol, street drugs, or suffer from mental health disorders such as PTSD, depression, anxiety and trauma. See more information on what treatments are used for these:

"We've incorporated holistic medicine and methodically weaved it with sacred plant medicine to have a better synergistic never before seen outcome. In the last 10 years, we have therapeutically, safely and humanely given people sacred plant medicines like Ibogaine, DMT, Changa, 5-MEO, Kambo, Psilocybin, mushrooms, and much more,"added Tabaie.

The organization is looking for investors and partners to help finance and push this revolutionary vision forward. For more information about The Holistic Sanctuary and investor relations, please send an email or call +1-310-601-7805 or visit their website at http://www.theholisticsanctuary.com.

About The Holistic Sanctuary

The Holistic Sanctuary is a world-class holistic medical spa that uses cutting-edge and advanced therapies from around the world. It uses powerful modalities to cure, heal, and reverse illnesses and diseases that Western medical professionals have said are incurable. It is not a drug rehab, more along the lines of a luxury treatment center that transforms lives. It helps people to recover from depression, any type of addiction, PTSD, stress, anxiety, as well as other mental health problems. The centers use a combination of natural therapies to help people recover mentally, physically and emotionally. Unlike mainstream doctors, rehabs, and treatment centers, The Holistic Sanctuary avoids the use of outdated theories, ineffective therapies and addiction to toxic medications and drugs. Instead, it addresses the root causes of these illnesses, improves physical and mental health and alleviates the illnesses.

Media Contact

Company Name: The Holistic Sanctuary

Contact Person: Investor Relations

Email: info@theholisticsanctuary.com

Phone: +1-310-601-7805

Address: 1212 Wilshire Blvd.

City:Beverly Hills

State:California

Website: http://www.theholisticsanctuary.com

Related Images

the-holistic-sanctuary.png The Holistic Sanctuary Most Exclusive Healing Center In The World, The Holistic Sanctuary Healing Center Offers Holistic Stem Cells, Plant Medicine and Powerful Therapies for Lupus, Lyme, MS, ALS, Addiction, Depression, PTSD, Stem Cell Therapies to Heal Clients Naturally

Related Video

Visit link:
The Holistic Sanctuary Announces Exciting Plans to Expand Over Next 4 Years and Save More Lives - WFMZ Allentown

Cord Stem Cell Banking Market Analysis 2020 With COVID 19 Impact Analysis| Leading Players, Business Prospects, In-depth Analysis Research Report…

Global stem cell banking market is set to witness a substantial CAGR of 11.03% in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. The increased market growth can be identified by the increasing procedures of hematopoietic stem cell transplantation (HSCT), emerging technologies for stem cell processing, storage and preservation. Increasing birth rates, awareness of stem cell therapies and higher treatment done viva stem cell technology.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-banking-market&pm

Competitive Analysis:

Global stem cell banking market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of inflammatory disease drug delivery market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Competitors:

Few of the major competitors currently working in global inflammatory disease drug delivery market are: NSPERITE N.V, Caladrius, ViaCord, CBR Systems, Inc, SMART CELLS PLUS, LifeCell International, Global Cord Blood Corporation, Cryo-Cell International, Inc., StemCyte India Therapeutics Pvt. Ltd, Cordvida, ViaCord, Cryoviva India, Vita34 AG, CryoHoldco, PromoCell GmbH, Celgene Corporation, BIOTIME, Inc., BrainStorm Cell Therapeutics and others

Market Definition:Global Stem Cell Banking Market

Stem cells are cells which have self-renewing abilities and segregation into numerous cell lineages. Stem cells are found in all human beings from an early stage to the end stage. The stem cell banking process includes the storage of stem cells from different sources and they are being used for research and clinical purposes. The goal of stem cell banking is that if any persons tissue is badly damaged the stem cell therapy is the cure for that. Skin transplants, brain cell transplantations are some of the treatments which are cured by stem cell technique.

Cord Stem Cell Banking MarketDevelopment and Acquisitions in 2019

In September 2019, a notable acquisition was witnessed between CBR and Natera. This merger will develop the new chances of growth in the cord stem blood banking by empowering the Nateras Evercord branch for storing and preserving cord blood. The advancement will focus upon research and development of the therapeutic outcomes, biogenetics experiment, and their commercialization among the global pharma and health sector.

Cord Stem Cell Banking MarketScope

Cord Stem Cell Banking Marketis segmented on the basis of countries into U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

All country based analysis of the cord stem cell banking marketis further analyzed based on maximum granularity into further segmentation. On the basis of storage type, the market is segmented into private banking, public banking. On the basis of product type, the market is bifurcated into cord blood, cord blood & cord tissue. On the basis of services type, the market is segmented into collection & transportation, processing, analysis, storage. On the basis of source, market is bifurcated into umbilical cord blood, bone marrow, peripheral blood stem, menstrual blood. On the basis of indication, the market is fragmented into cerebral palsy, thalassemia, leukemia, diabetes, autism.

Cord stem cell trading is nothing but the banking of the vinculum plasma cell enclosed in the placenta and umbilical muscle of an infant. This ligament plasma comprises the stem blocks which can be employed in the forthcoming time to tackle illnesses such as autoimmune diseases, leukemia, inherited metabolic disorders, and thalassemia and many others.

Market Drivers

Increasing rate of diseases such as cancers, skin diseases and others Public awareness associated to the therapeutic prospective of stem cells Growing number of hematopoietic stem cell transplantations (HSCTs) Increasing birth rate worldwide

Market Restraint

High operating cost for the therapy is one reason which hinders the market Intense competition among the stem cell companies Sometimes the changes are made from government such as legal regulations

Key Pointers Covered in the Cord Stem Cell Banking MarketIndustry Trends and Forecast to 2026

Market Size Market New Sales Volumes Market Replacement Sales Volumes Market Installed Base Market By Brands Market Procedure Volumes Market Product Price Analysis Market Healthcare Outcomes Market Cost of Care Analysis Market Regulatory Framework and Changes Market Prices and Reimbursement Analysis Market Shares in Different Regions Recent Developments for Market Competitors Market Upcoming Applications Market Innovators Study

Key Developments in the Market:

In August, 2019, Bayer bought BlueRock for USD 600 million to become the leader in stem cell therapies. Bayer is paying USD 600 million for getting full control of cell therapy developer BlueRock Therapeutics, promising new medical area to revive its drug development pipeline and evolving engineered cell therapies in the fields of immunology, cardiology and neurology, using a registered induced pluripotent stem cell (iPSC) platform. In August 2018, LifeCell acquired Fetomed Laboratories, a provider of clinical diagnostics services. The acquisition is for enhancement in mother & baby diagnostic services that strongly complements stem cell banking business. This acquisition was funded by the internal accruals which is aimed to be the Indias largest mother & baby preventive healthcare organization.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-stem-cell-banking-market&pm

Research objectives

To perceive the most influencing pivoting and hindering forces in Cord Stem Cell Banking Market and its footprint in the international market. Learn about the market policies that are being endorsed by ruling respective organizations. To gain a perceptive survey of the market and have an extensive interpretation of the Cord Stem Cell Banking Market and its materialistic landscape. To understand the structure of Cord Stem Cell Banking Market by identifying its various sub segments. Focuses on the key global Cord Stem Cell Banking Market players, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). To project the consumption of Cord Stem Cell Banking Market submarkets, with respect to key regions (along with their respective key countries). To strategically profile the key players and comprehensively analyze their growth strategies To analyze the Cord Stem Cell Banking Market with respect to individual growth trends, future prospects, and their contribution to the total market.

Customization of the Report:

All segmentation provided above in this report is represented at country level All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @[emailprotected]

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

See the original post:
Cord Stem Cell Banking Market Analysis 2020 With COVID 19 Impact Analysis| Leading Players, Business Prospects, In-depth Analysis Research Report...

Advanced Therapy Medicinal Products Market Research Report by Therapy Type – Global Forecast to 2025 – Cumulative Impact of COVID-19 – GlobeNewswire

September 18, 2020 20:07 ET | Source: ReportLinker

New York, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Advanced Therapy Medicinal Products Market Research Report by Therapy Type - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05953100/?utm_source=GNW

The Global Advanced Therapy Medicinal Products Market is expected to grow from USD 2,946.38 Million in 2019 to USD 6,524.94 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 14.16%.

Market Segmentation & Coverage: This research report categorizes the Advanced Therapy Medicinal Products to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Therapy Type , the Advanced Therapy Medicinal Products Market studied across CAR-T Therapy, Cell Therapy, Gene Therapy, and Tissue Engineered Product. The Cell Therapy further studied across Non-stem Cell Therapy and Stem Cell Therapy.

Based on Geography, the Advanced Therapy Medicinal Products Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Advanced Therapy Medicinal Products Market including AveXis, Inc., Bluebird Bio, Inc., Celgene Corporation, Gilead Lifesciences, Inc., JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc., MEDIPOST, Novartis AG, Organogenesis Inc., PHARMICELL Co., Ltd, Spark Therapeutics, Inc., UniQure N.V., and Vericel Corporation.

FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Advanced Therapy Medicinal Products Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on the market offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as: 1. What is the market size and forecast of the Global Advanced Therapy Medicinal Products Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Advanced Therapy Medicinal Products Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Advanced Therapy Medicinal Products Market? 4. What is the competitive strategic window for opportunities in the Global Advanced Therapy Medicinal Products Market? 5. What are the technology trends and regulatory frameworks in the Global Advanced Therapy Medicinal Products Market? 6. What are the modes and strategic moves considered suitable for entering the Global Advanced Therapy Medicinal Products Market? Read the full report: https://www.reportlinker.com/p05953100/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Continued here:
Advanced Therapy Medicinal Products Market Research Report by Therapy Type - Global Forecast to 2025 - Cumulative Impact of COVID-19 - GlobeNewswire

Stem Cell Therapy Products Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19…

The globalStem Cell Therapy Products Marketis carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Stem Cell Therapy Products market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Stem Cell Therapy Products market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Stem Cell Therapy Products market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Stem Cell Therapy Products market.

Leading players of the global Stem Cell Therapy Products market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Stem Cell Therapy Products market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Stem Cell Therapy Products market. It also provides useful recommendations for new as well as established players of the global Stem Cell Therapy Products market.

To know How COVID-19 Pandemic Will Impact This Market/Industry -Request sample copy of this report: https://www.reportsandmarkets.com/sample-request/global-and-chinese-stem-cell-therapy-products-industry-2018-market-research-report?utm_source=verdant-news&utm_medium=24

Major Players: ask for sample

Regions and Countries:U.S, Canada, France, Germany, UK, Italy, Rest of Europe, India, China, Japan, Singapore, South Korea, Australia, Rest of APAC, Brazil, Mexico, Argentina, Rest of LATAM, Saudi Arabia, South Africa, UAE.

Report Objectives

For More Information or Query or Customization Before Buying, Visit at -: https://www.reportsandmarkets.com/sample-request/global-and-chinese-stem-cell-therapy-products-industry-2018-market-research-report?utm_source=verdant-news&utm_medium=24

Table of Contents

Report Overview:It includes major players of the global Stem Cell Therapy Products market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Stem Cell Therapy Products market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Stem Cell Therapy Products market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Stem Cell Therapy Products market by application, it gives a study on the consumption in the global Stem Cell Therapy Products market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Stem Cell Therapy Products market are profiled in this section. The analysts have provided information about their recent developments in the global Stem Cell Therapy Products market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Stem Cell Therapy Products market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Stem Cell Therapy Products market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Stem Cell Therapy Products market.

Key Findings:This section gives a quick look at important findings of the research study.

About Us:

Market research is the new buzzword in the market, which helps in understanding the market potential of any product in the market. Reports And Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

[emailprotected]

Ph: +1-352-353-0818 (US)

Go here to see the original:
Stem Cell Therapy Products Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19...

Treatment, Access to Caregivers Among Factors Affecting QOL in MM – AJMC.com Managed Markets Network

Investigators from the First Affiliated Hospital of Sun-Yat Sen, including corresponding author Juan Li, PhD, noted that while QoL has been studied extensively in patients with MM, most of the research has been conducted on western populations, and such studies tend to be based on clinical trial data, which they said is not representative of the wider population of patients with MM.

In the current study, the authors sent out a questionnaire to people with MM in all 27 provinces of China. A total of 430 people responded, and they had an average age of 55.7 years.

The results of the survey showed a number of factors can affect HRQoL. Among them, patients who underwent autologous stem cell transplantation (ASCT) had higher HRQoL than those who did not have the transplant. However, toxicities were a major concern. A vast majority (91.5%) of patients on maintenance therapy said they intended to stop the treatment, mostly due to adverse events and the high cost of treatment.

The application of ASCT has significantly improved the prognosis of patients with MM and prolonged the OS of patients, Li and colleagues wrote. However, as patient survival is prolonged, patients experience different levels of pain due to treatment-related toxicities.

Patient HRQoL scores were improved when patients were diagnosed quickly, though the study found only 16.7% of patients were diagnosed within a month of the onset of symptoms. The reasons for the delayed diagnosis included lack of awareness of the severity of the condition, failure by the hospital to confirm the diagnosis quickly, and inability to pay for care.

Access to a caregiver benefited patients HRQoL, but more than one-third (38.4%) did not have a caregiver. More than half of the patients (56.3%) said they had to travel to another city to receive care, another factor that negatively impacted their scores on functional and symptom measures, though it did not impact overall HRQoL, the authors said.

Four in 10 patients in the study reported psychosocial challenges, such as anxiety and depression.

Patients live with the uncertainty of a treatable but incurable cancer; they worry about how their illness will progress and are concerned about death and dying, the authors said. Overall, these findings suggest that patients need more psychological support during all phases of treatment.

Basic demographic factors, like age and sex, yielded mixed results. In a univariate analysis, both factors appeared to be associated with HRQoL. However, when investigators performed a multiple linear regression analysis, neither factor emerged as an independent predictor of HRQOL.

The authors said these data should provide clinicians with tools to identify patients who are at risk of diminished HRQoL.

Efforts should be made to identify persons at risk of low HRQOL earlier and improve the overall quality of life of these patients in China, they concluded.

Reference

Li X, Liu J, Chen M, et al. Health-related quality of life of patients with multiple myeloma: A real-world study in China. Cancer Med. Published online September 2, 2020. doi:10.1002/cam4.3391

Read more from the original source:
Treatment, Access to Caregivers Among Factors Affecting QOL in MM - AJMC.com Managed Markets Network

Value of Animal Stem Cell Therapy Market Predicted to Surpass US$ by the of 2017 2025 – Daily Research Chronicle

In this report, the global Animal Stem Cell Therapy market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Animal Stem Cell Therapy market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Animal Stem Cell Therapy market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Animal Stem Cell Therapy market to assist our clients arrive at beneficial business decisions.

The Animal Stem Cell Therapy market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Animal Stem Cell Therapy market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14941

Resourceful insights enclosed in the report:

The major players profiled in this Animal Stem Cell Therapy market report include:

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14941

The market report addresses the following queries related to the Animal Stem Cell Therapy market:

The study objectives of Animal Stem Cell Therapy Market Report are:

To analyze and research the Animal Stem Cell Therapy market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Animal Stem Cell Therapy manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Animal Stem Cell Therapy market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the Animal Stem Cell Therapy market.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14941

Continued here:
Value of Animal Stem Cell Therapy Market Predicted to Surpass US$ by the of 2017 2025 - Daily Research Chronicle

New medicines in the pipeline to treat sickle cell disease – BioWorld Online

The CDC estimates that sickle cell disease affects well over 100,000 Americans, with the disease occurring most often in African Americans. September has been designated as National Sickle Cell Awareness month designed to focus attention on the ongoing research in this field and the need for new treatments. The sector can certainly point to the significant progress that has taken place during the past few years, with new medicines reaching the market and several novel therapeutics with new mechanisms of action advancing in the pipeline.

Ted Love, president and CEO of Global Blood Therapeutics Inc. (GBT), said 2019 was a landmark year with the FDA approval of two new novel therapies to treat sickle cell disease. He was speaking at the virtual annual Sickle Cell Disease (SCD) Therapeutics Conference this week. His company, together with the Sickle Cell Disease Association of America, was hosting the one-day event featuring discussions on the latest advances and future trends.

Approvals

The key manifestation of the inherited blood disorder is that red blood cells (RBCs) are abnormally shaped (crescent), which restricts their flow in blood vessels and limits oxygen delivery to the bodys tissues, leading to severe pain and organ damage. The condition is also characterized by severe chronic inflammation that results in vaso-occlusive crisis (VOC) where patients experience episodes of extreme pain and organ damage.

Late November, GBT gained accelerated approval for its Oxbryta (voxelotor) tablets for the treatment SCD in adults and pediatric patients 12 and older. The agencys green light came less than two weeks after it gave the go-ahead to Novartis AG for Adakveo (crizanlizumab) to reduce the frequency of VOCs in adult and pediatric patients ages 16 and older with SCD.

According to Love, Oxbryta is a new class of therapy binding to hemoglobin and stabilizing RBCs in an oxygenated state and inhibiting deoxygenated sickle hemoglobin polymerization, making cells less likely to bind together and form the distinctive sickle shape.

The launch of the drug has gone well since it was approved, he said in the companys second-quarter financial report and business update, despite the impact of COVID-19. Net sales in the period reached $31.5 million, well ahead of the Streets expectations. Going forward, the company is planning to expand the potential use of Oxbryta for the treatment of SCD in children as young as 4 years old and also seek marketing authorization in Europe for Oxbryta to treat hemolytic anemia in SCD patients ages 12 and older with a marketing authorization application being submitted to the EMA by the middle of next year.

Pipeline progress

Cambridge, Mass.-based Agios Pharmaceuticals Inc. is working on mitapivat (AG-348), an investigational, oral, small-molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase-R (PKR) enzymes, in patients with SCD. The compound has been shown to decrease 2,3-diphosphoglycerate (2,3-DPG) and increase adenosine triphosphate (ATP), and through that mechanism, it may reduce hemoglobin (Hb) S polymerization and red blood cell sickling. In June, the company reported that clinical proof of concept had been established based on a preliminary analysis in a phase I trial being conducted in collaboration with the U.S. NIH as part of a cooperative research and development agreement.

The ongoing study had enrolled nine patients, with eight completing all planned dose levels of mitapivat. Seven of eight patients who completed all dose levels experienced a Hb increase, with five of eight patients (63%) achieving a hemoglobin increase of 1 g/dL from baseline (range 1-2.7 g/dL). All five patients who achieved a hemoglobin increase of 1 g/dL did so at doses of 50 mg BID or lower. Decreases in 2,3-DPG and increases in ATP levels were observed, consistent with the proposed mechanism of action and comparable to that observed in healthy volunteer studies with mitapivat.

The company said it expects to report data from ACTIVATE and ACTIVATE-T, its two global pivotal trials for mitapivat in adults with pyruvate kinase deficiency, between the end of 2020 and mid-2021.

Watertown, Mass.-based Forma Therapeutics Holdings Inc., which made its public debut this year, also has a selective RBC pyruvate kinase-R activator in its pipeline for treating SCD. FT-4202 is being evaluated in a phase I trial in SCD patients ages 12 and older and has been granted fast track, rare pediatric and orphan drug designations. The compound is a potent activator of pyruvate kinase-R designed to improve RBC metabolism, function and survival by decreasing 2,3 DPG and increasing ATP, potentially resulting in both increased hemoglobin levels and reduced VOCs.

Olinciguat, an oral guanylate cyclase (sGC) stimulator, being developed by Cyclerion Therapeutics Inc., has completed the treatment period in its STRONG-SCD study with a total of 70 patients randomized. The placebo-controlled, dose-ranging study is designed to evaluate safety, tolerability and pharmacokinetics, as well as to explore effects on daily symptoms and biomarkers of disease activity when dosed over a 12-week treatment period. Top-line results are expected this year. Olinciguat is a compound that aims to stimulate sGC production, leading to the production of a signaling molecule called cyclic guanosine monophosphate (cGMP). High levels of cGMP help reduce inflammation in blood vessels, decrease adhesion between RBCs, and allow for improved blood flow by increasing the availability of nitric oxide.

Boston-based Imara Inc. is developing IMR-687, a small-molecule inhibitor of PDE9 that degrades cyclic guanosine monophosphate (cGMP), an active signaling molecule that plays a role in vascular biology. The company said that lower levels of cGMP are often found in people with SCD and beta-thalassemia and are associated with impaired blood flow, increased inflammation, greater cell adhesion and reduced nitric oxide-mediated vasodilation. Blocking PDE9 acts to increase cGMP levels, which are associated with reactivation of fetal hemoglobin.

In August, the company dosed the first patient in its Ardent phase IIb trial of IMR-687 for adult patients with SCD. The planned primary efficacy objective is to evaluate the proportion of all patients with fetal hemoglobin (HbF) response, defined as an increase of 3% in HbF from baseline to week 24, compared to placebo.

Gene therapy/gene editing

Since SCD is a monogenic disease condition, researchers believe that it would be a good candidate for gene therapy therapeutic approaches. For example, significant progress is being made by Cambridge, Mass.-based Bluebird Bio Inc. with lentiglobin, its lentiviral-based gene therapy that inserts an anti-sickling beta-globin variant into CD34-positive cells, progenitors of red blood cells.

At the virtual European Hematology Association (EHA) meeting in June, it reported new data from its ongoing phase I/II study involving adult and adolescent patients with SCD that showed a near-complete reduction of serious VOCs and acute chest syndrome. The company expects to submit a BLA to the FDA for the gene therapy next year.

Crispr Therapeutics AG and Vertex Pharmaceuticals Inc. are progressing CTX-001, an investigational, autologous, CRISPR/Cas9 gene-edited hematopoietic stem cell therapy being evaluated for patients suffering from severe hemoglobinopathies. At EHA, the companies reported that in the phase I/II Climb-121 study, at nine months after CTX-001 infusion, the first treated patient was free of VOCs, was transfusion independent and had total hemoglobin levels of 11.8 g/dL, 46.1% fetal hemoglobin and F-cells (erythrocytes expressing fetal hemoglobin) of 99.7%.

Last month, Cambridge, Mass.-based Editas Medicine Inc., a genome editing company, reported that the FDA had granted rare pediatric disease designation for EDIT-301, an experimental, autologous cell medicine, being developed as a potentially best-in-class, durable medicine for SCD. The company plans to file an investigational new drug application for EDIT-301 by the end of this year. EDIT-301 comprises sickle patient CD34+ cells genetically modified using a hCRISPR/Cas12a (also known as Cpf1) ribonucleoprotein to edit the HBG1/2 promoter region in the beta-globin locus. Red blood cells derived from EDIT-301 CD34+ cells demonstrate a sustained increase in fetal hemoglobin (HbF) production.

In its second-quarter financial report and business update, Beam Therapeutics Inc. announced the nomination of its first two adenine base editing development candidates, BEAM-101, targeting patients with hereditary persistence of fetal hemoglobin, and BEAM-102 (Makassar variant), both aimed at correcting SCD.

New Initiative

The NIH, which reports it spends approximately $100 million on sickle cell disease research, announced that is has launched The Cure Sickle Cell Initiative designed to speed the development of cures for the disease. It will take advantage of the latest genetic discoveries and technological advances to progress the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.

Aided by research partners, the initiative will establish a national data warehouse of genetic therapies for sickle cell disease and conduct comparative analyses of therapeutic approaches to assess both clinical and cost effectiveness. National networks will also be created to make it easier for patients and providers to interact with the research, clinical trials, and other activities.

Link:
New medicines in the pipeline to treat sickle cell disease - BioWorld Online

Global Stem Cell manufacturing Market Analysis 2020 With COVID 19 Impact Analysis| Leading Players, Business Prospects, In-depth Analysis Research…

This Global Stem Cell manufacturing Market research report offers an array of insights about industry and business solutions that will support to stay ahead of the competition. A systematic investment analysis is also underlined in this report which forecasts impending opportunities for the market players. The market report is an outcome of persistent and numerous efforts lead by knowledgeable forecasters, innovative analysts and brilliant researchers who carry out detailed and diligent research on different markets, trends and emerging opportunities in the consecutive direction for the business needs.

The credible Global Stem Cell manufacturing Market report provides company profiling of key players in the industry, carefully analyzing their core competencies, and drawing a competitive landscape for the market. The data involved in this market report can be very necessary when it comes to dominating the market or making a mark in the market as a new emergent. To generate the best market research report, a range of objectives of the marketing research are required to be kept in mind. Market research analysis and data lend a hand to businesses for the planning of production, product launches, costing, inventory, purchasing and marketing strategies.

Stem Cell Manufacturing Marketis expected to reach USD 16.51 Billion by 2025, from USD 10.28 Billion in 2017 growing at a CAGR of 6.1% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2017, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Get Sample Report PDF | @http://databridgemarketresearch.com/request-a-sample/?dbmr=global-artificial-intelligence-market

The Global Stem Cell Manufacturing Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of stem cell manufacturing market for global, Europe, North America, Asia Pacific and South America.

Major Market competitors/players: Global Stem Cell Manufacturing Market

Some of the major players operating in the stem cell manufacturing market are Thermo Fisher Scientific. Merck Group, Becton, Dickinson and Company. Holostem Advanced Therapies, JCR Pharmaceuticals, Organogenesis Inc, Osiris Therapeutics, Osiris Therapeutics, Vericel Corporation, AbbVie, American CryoStem, AM-Pharma, Anterogen.Co.,Ltd, Astellas Pharma, Bristol-Myers Squibb, Apceth Biopharma, Cellular Dynamics International, Rheacell, Takeda Pharmaceutical, Teva Pharmaceutical Industries Ltd. ViaCyte, VistaGen Therapeutics Inc, Translational Biosciences, GlaxoSmithKline plc, Daiichi Sankyo Company, Limited, among others.

Global Stem Cell manufacturing Market,By Application (Research Applicationsand Clinical Applicationsand Cell and Tissue Banking), By Product (Stem Cell Line, Instruments, Culture Media and Consumables), By End Users (Hospitals and Surgical Centers, Pharmaceutical and Biotechnology Companies, Clinics, Community Healthcare, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2025

Table of Contents:

Highlights of the Study

Inquire about this report from our experts @https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-manufacturing-market

Major Market Drivers:

Report Scope

Our purpose is to serve you, the most customised in-depth Market access data. Our plethora of titles, made us one of the most searched market research library across the globe. We work with the most esteemed Publishers around the globe who caters vast industries. We are quick and fragile, when it comes to your various queries, and we ensure our team cater your needs to the best of our abilities, we promise to stay by your side for both pre and post sales servicing, as we believe in long everlasting symbiotic relationship.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email:[emailprotected]

Original post:
Global Stem Cell manufacturing Market Analysis 2020 With COVID 19 Impact Analysis| Leading Players, Business Prospects, In-depth Analysis Research...